BlackRock Advisors’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
$43M Sell
1,375,401
-2,261,793
-62% -$73.3M 0.04% 344
2016
Q3
$146M Sell
3,637,194
-251,304
-6% -$9.46M 0.15% 160
2016
Q2
$129M Buy
3,888,498
+324,033
+9% +$11.1M 0.13% 174
2016
Q1
$105M Buy
3,564,465
+54,699
+2% +$1.51M 0.11% 191
2015
Q4
$92.4M Buy
3,509,766
+281,982
+9% +$7.32M 0.1% 213
2015
Q3
$76.5M Sell
3,227,784
-762,378
-19% -$18.4M 0.08% 237
2015
Q2
$94.7M Sell
3,990,162
-798,756
-17% -$18M 0.1% 208
2015
Q1
$114M Buy
4,788,918
+186,690
+4% +$4.19M 0.12% 199
2014
Q4
$97.7M Sell
4,602,228
-343,392
-7% -$6.9M 0.1% 218
2014
Q3
$84.2M Buy
4,945,620
+107,262
+2% +$1.69M 0.08% 241
2014
Q2
$69.2M Buy
4,838,358
+488,046
+11% +$6.62M 0.07% 280
2014
Q1
$53.8M Sell
4,350,312
-67,116
-2% -$774K 0.05% 330
2013
Q4
$48.4M Buy
4,417,428
+941,634
+27% +$10.6M 0.05% 353
2013
Q3
$40.3M Buy
3,475,794
+2,548,224
+275% +$29.8M 0.04% 375
2013
Q2
$10.4M Buy
+927,570
New +$11M 0.01% 765

Other funds holding EW

BlackRock Advisors's EW Position: Q4 2016 in Review

BlackRock Advisors reduced its Edwards Lifesciences (EW) stake by 62% in Q4 2016, selling an estimated $73.3M and leaving 1,375,401 shares worth $43M. The position accounts for 0.04% of the portfolio, ranked #344.

BlackRock Advisors first reported a position in EW in Q2 2013 and has held it in 15 quarters since. The position peaked at $146M in Q3 2016. 686 funds tracked by Wall St. Rank hold EW as of Q4 2016.

  • BlackRock Advisors held 1,375,401 shares of Edwards Lifesciences worth $43M as of Q4 2016.
  • BlackRock Advisors sold 2,261,793 Edwards Lifesciences shares in Q4 2016, an estimated $73.3M.
  • Edwards Lifesciences made up 0.04% of BlackRock Advisors's portfolio in Q4 2016, its #344 holding.
  • BlackRock Advisors first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Advisors's Edwards Lifesciences position peaked at $146M in Q3 2016.
  • 686 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.